Trials / Recruiting
RecruitingNCT02292641
Beyond TME Origins
Investigating the Origins of Pelvic Recurrence in Colorectal Cancer
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 383 (estimated)
- Sponsor
- Imperial College London · Academic / Other
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
All patients with recurrent colorectal cancer in the pelvis are eligible. The original primary tumour staging scans and resected surgical specimen needs to be available. Patients' recurrence will be staged using our proposed MRI classification. We will be assessing the original primary staging scans and histopathology to learn about risk factors for recurrence. We will record treatment for the recurrence, and patients will be followed up for three years.
Detailed description
A prospective and retrospective cohort study to improve surgical and treatment planning using an imaging assessment proforma of advanced and recurrent colorectal cancers. This involves the implementation of imaging assessment proformas describing anatomic pelvic compartments and aetiology of disease recurrence for treatment planning.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | New Radiological Staging Classification system for patients with advanced and recurrent colorectal cancer undergoing pelvic exenterative surgery | Currently there are no validated criteria or guidelines for judging whether advanced primary or recurrent colorectal cancer can be successfully removed and for selecting which patients should undergo this form of more radical surgery as is exenterative surgery. We are proposing that by validating the detailed evaluation of imaging of the tumour distribution within the pelvis using a new radiological staging classification, this will enable clear selection criteria to be established and will improve surgical planning. |
Timeline
- Start date
- 2014-09-25
- Primary completion
- 2026-12-01
- Completion
- 2031-12-01
- First posted
- 2014-11-17
- Last updated
- 2024-10-17
Locations
4 sites across 2 countries: Norway, United Kingdom
Source: ClinicalTrials.gov record NCT02292641. Inclusion in this directory is not an endorsement.